CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immun...(that this new data is encouraging and su...)

Date:11/9/2009

that this new data is encouraging and supportive of our H1N1 treatment for hospitalized patients where the goal is to produce a specific anti H1N1 immune response that will steer the immune system towards protection and away from a cytokine storm which may be responsible for many patients' deaths."

CEL-SCI's L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) technology allows the Company to direct an immune response against specific disease epitopes. In the case of CEL-SCI's investigational LEAPS-H1N1 treatment, this involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu. This is intended to enable stimulation of the specifically-needed immune responses, while avoiding the administration of regions of H1N1, and other viruses, which may exacerbate the problem of cytokine storm, which CEL-SCI scientists believe may be involved in the death of some H1N1 patients.

The concept behind the L.E.A.P.S. technology is to directly mimic cell/cell interactions on the T-cell surface with synthetic peptides. The L.E.A.P.S. constructs containing the antigenic disease epitope linked to a Immune / T-cell binding ligand (I/TCBL) can be manufactured by peptide synthesis or by covalently linking the two peptides. Depending upon the type of L.E.A.P.S. construct and I/TCBL used, CEL-SCI is able to direct the outcome of the immune response towards the development of T-cell function with primarily effector T-cell functions (T Lymphocyte; helper/effector T lymphocyte, type 1 or 2 [Th1 or Th2], cytotoxic [Tc] or suppressor [Ts]). Therefore, it would appear that the L.E.A.P.S. construct represents a chimeric peptide with bi-functional behavior.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine® which is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing a treatment for hospitalized H1N1 patients usi
'/>"/>

SOURCE CEL-SCI Corporation Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related biology technology :

1. CEL-SCI to Commence First Clinical Study with Hospitalized H1N1 Infected Patients
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI Files Patent Application to Support Companys Treatment for More Virulent Strain of H1N1 Swine and Other Influenza Viruses
4. CEL-SCI Signs Definitive Agreement to Raise $5 Million in Registered Direct Offering
5. CEL-SCI Developing Immune-Based Treatment Against Swine and Other H1N1 Flu Viruses Using Proprietary L.E.A.P.S. Technology
6. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
7. CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease
8. CEL-SCI Corporation to Launch Aseptic Filling for Stem Cell Produced Therapies and Other Biological Products
9. CEL-SCI Corporation Announces 2008 Financial Results
10. CEL-SCI Corporation Releases Letter to Shareholders
11. Updated Pictures of CEL-SCI Manufacturing Facility Available Online